|
|
|
|
FrovaPharmaLive.com (press release), Frovatriptan, marketed as Frova(R) in the US by Vernalis' partner, Endo Pharmaceuticals Inc., is a selective 5-HT1B/1D receptor agonist approved as an acute ... CSFB Reiterates Outperform On Vernalis Dec 20, 2005 New Ratings ...focused and well-incentivised specialist partner for a product that has historically lacked commercial commitment, "and second, the fact that Frova has already ... NEW AMERICA Dec 29, 2005 Investor's Business Daily (subscription) The drug, Frova, is indicated for acute migraine attacks. Endo plans to seek approval to market Frova for a new indication — menstrual-related migraines. ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |